Abstracts tagged "spondylarthropathy and tumor necrosis factor (TNF)"

Abstract Number: 1697 • 2015 ACR/ARHP Annual Meeting
Obstructive Sleep Apnea and Fatigue in Inflammatory Arthritis Patients Taking TNF-Inhibitors
Brian Breviu¹, Tawnie Braaten¹, Daniel Clegg² and Jessica Walsh³, ¹Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Fatigue improves with TNF-inhibition (TNF-i) in people with inflammatory arthritis (IA), but the mechanistic relationships between TNF-i and fatigue are not well understood. Since…
Abstract Number: 854 • 2014 ACR/ARHP Annual Meeting
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial
Chi Chiu Mok¹, Angela Li², Kar Li Chan¹ and Ling Yin Ho¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Radiology, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To compare the efficacy of golimumab(GLM) and pamidronate(PAM) in the treatment of SpA.Methods Inclusion criteria: (1) patients ≥18 years of age; (2) fulfills the…
Abstract Number: 2219 • 2012 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates After One Year of Treatment with Etanercept – results of the Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiß⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum Berlin, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration < 5 years we assessed whether there is a difference to etanercept (ETA)…
Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Violeta Rosario¹, Sonia Cabrera¹, Virginia Ruiz-Esquide³, Maria Eugenia Gomez-Caballero¹, Jose A. Gómez-Puerta¹, Julio Ramirez¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…
Abstract Number: 571 • 2012 ACR/ARHP Annual Meeting
Description of Distribution of Active Inflammatory Lesions On Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine in Patients with Early Axial Spondyloarthritis – Analysis of the Esther Trial Baseline Data
In-Ho Song¹, Christian Althoff², Hildrun Haibel¹, Joachim Listing³, Anja Weiß⁴, Bruce Freundlich⁵, Martin Rudwaleit⁶ and Joachim Sieper⁷, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Endokrinologikum Berlin, Berlin, Germany, ⁷Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To address the question whether active inflammation starts at specific sites of the sacroiliac joints (SI-joints) and/ or the spine. Methods: Wb-MRIs of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].